Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00757744 · ClinicalTrials.gov registry record · Phase 3

Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China

A Phase 3 study, sponsored by Yale University.

Completed
Registry status
Phase 3
Development phase
45
Enrollment target

NCT00757744: Completed Phase 3 study, sponsored by Yale University.

NCT00757744 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 45 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00757744, a Phase 3 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 3
Development phase
45 participants
Enrollment target

Study Summary

A randomized clinical trial evaluating the reduction of HIV risk behaviors and drug use when providing integrated behavioral drug and HIV risk reduction counseling (BDRC) along with methadone maintenance treatment in Wuhan, China

Interventions

  • BEHAVIORAL Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
  • BEHAVIORAL Drug counseling

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2007-09
Est. Completion 2010-09
Phase Phase 3
Yale University

1,492 total trials

What the finished NCT00757744 record still lists

NCT00757744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Behavioral Drug and HIV Risk Reduction Counseling (BDRC) is the first listed.

NCT00757744 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00757744 about?

NCT00757744 is a clinical study titled "Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China". A randomized clinical trial evaluating the reduction of HIV risk behaviors and drug use when providing integrated behavioral drug and HIV risk reduction counseling (BDRC) along with methadone maintenance treatment in Wuhan, China

What is the current status of trial NCT00757744?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2007-09. Estimated completion is 2010-09.

What interventions are being tested in trial NCT00757744?

The interventions under investigation include: Behavioral Drug and HIV Risk Reduction Counseling (BDRC) (BEHAVIORAL), Drug counseling (BEHAVIORAL).

Who is sponsoring clinical trial NCT00757744?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00757744's enrollment target sits among peer trials

45 1870th of 2000 higher than 127 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00757744, the US trial registry maintained by the National Library of Medicine. NCT00757744 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.